US 12,460,002 B2
CD3 binding molecules
Pieter Fokko Van Loo, Utrecht (NL)
Assigned to Merus N.V., Utrecht (NL)
Appl. No. 17/438,768
Filed by Merus N.V., Utrecht (NL)
PCT Filed Mar. 27, 2020, PCT No. PCT/NL2020/050214
§ 371(c)(1), (2) Date Sep. 13, 2021,
PCT Pub. No. WO2020/204708, PCT Pub. Date Oct. 8, 2020.
Claims priority of application No. 19166345 (EP), filed on Mar. 29, 2019; and application No. 19200931 (EP), filed on Oct. 1, 2019.
Prior Publication US 2022/0356251 A1, Nov. 10, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2809 (2013.01) [A61P 35/00 (2018.01); C07K 16/283 (2013.01); C07K 16/2863 (2013.01); C07K 2317/31 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 30 Claims
OG exemplary drawing
 
1. An antigen-binding protein that binds human CD3 comprising an antibody variable domain comprising a heavy chain variable region and a light chain variable region wherein the heavy chain variable region comprises:
a CDR1, CDR2 and CDR3 comprising the amino acid sequence:
 
 CDR1: 
 
 (SEQ ID NO: 42)
 
 SFGIS
 
 
 
 CDR2: 
 
 (SEQ ID NO: 43)
 
 GFIPVLGTANYAQKFQG 
 
 
 
 CDR3: 
 
 (SEQ ID NO: 44)
 
 RGNWNPFDP;
or
comprising the amino acid sequence:
 
 CDR1: 
 
 (SEQ ID NO: 51)
 
 SKTFTIS;
 
 
 
 CDR2: 
 
 (SEQ ID NO: 52)
 
 GIIPLFGTITYAQKFQG;
 
 
 
 CDR3: 
 
 (SEQ ID NO: 53)
 
 RGNWNPFDP;
or
comprising the amino acid sequence:
 
 CDR1: 
 
 (SEQ ID NO: 60)
 
 SRTFTIS;
 
 
 
 CDR2: 
 
 (SEQ ID NO: 61)
 
 SIIPIFGTITYAQKFQG;
 
 
 
 CDR3:
 
 (SEQ ID NO: 62)
 
 RGNWNPFDP;
or
comprising the amino acid sequence:
 
 CDR1: 
 
 (SEQ ID NO: 84)
 
 SKTLTIS;
 
 
 CDR2: 
 
 (SEQ ID NO: 85)
 
 GIIPIFGSITYAQKFQD;
 
 
 CDR3: 
 
 (SEQ ID NO: 86)
 
 RGNWNPFDP,
or
comprising the amino acid sequence:
 
 CDR1: 
 
 (SEQ ID NO: 68)
 
 GSGIS;
 
 
 
 CDR2: 
 
 (SEQ ID NO: 69)
 
 GFIPFFGSANYAQKFRD;
 
 
 
 CDR3: 
 
 (SEQ ID NO: 70)
 
 RGNWNPLDP;
or
comprising the amino acid sequence:
 
 CDR1:
 
 (SEQ ID NO: 100)
 
 GSGIS;
 
 
 
 CDR2:
 
 (SEQ ID NO: 101)
 
 GFIPFFGSANYAQKFRD;
 
 
 
 CDR3: 
 
 (SEQ ID NO: 102)
 
 RGNWNPFDP;
or
comprising the amino acid sequence:
 
 CDR1: 
 
 (SEQ ID NO: 199)
 
 RFWIG;
 
 
 
 CDR2: 
 
 (SEQ ID NO: 200)
 
 IIYPGDSDTRYSPSFQG;
 
 
 
 CDR3: 
 
 (SEQ ID NO: 201)
 
 HIRYFDWSEDYHYYLDV; 
or
comprising the amino acid sequence:
 
 CDR1: 
 
 (SEQ ID NO: 208)
 
 RYWIG;
 
 
 
 CDR2: 
 
 (SEQ ID NO: 209)
 
 IIYPGDSDTRYSPSFQG;
 
 
 
 CDR3: 
 
 (SEQ ID NO: 210)
 
 NIRYFVWSEDYHYYMDV;
or
comprising the amino acid sequence:
 
 CDR1:
 
 (SEQ ID NO: 117)
 
 SYALS; 
 
 
 CDR2: 
 
 (SEQ ID NO: 118)
 
 GISGSGRTTWYADSVKG;
 
 
 CDR3: 
 
 (SEQ ID NO: 119)
 
 DGGYSYGPYWYFDL; 
or
comprising the amino acid sequence:
 
 CDR1: 
 
 (SEQ ID NO: 125)
 
 SYALS; 
 
 
 CDR2: 
 
 (SEQ ID NO: 126)
 
 AISGSGRTTWYADSVKG; 
 
 
 CDR3: 
 
 (SEQ ID NO: 127)
 
 DGGYTYGPYWYFDL; 
or
comprising the amino acid sequence:
 
 CDR1:
 
 (SEQ ID NO: 142)
 
 DYTMH;
 
 
 CDR2: 
 
 (SEQ ID NO: 143)
 
 DISWSSGSIGYADSVKG;
 
 
 CDR3: 
 
 (SEQ ID NO: 144)
 
 DHRGYGDYEGGGFDY;
or
comprising the amino acid sequence:
 
 CDR1: 
 
 (SEQ ID NO: 150)
 
 DYTMH;
 
 
 
 CDR2: 
 
 (SEQ ID NO: 151)
 
 DISWSSGSIGYADSVKG;
 
 
 
 CDR3: 
 
 (SEQ ID NO: 152)
 
 DHRGYGDYEGGGFDH;
or
comprising the amino acid sequence:
 
 CDR1: 
 
 (SEQ ID NO: 166)
 
 DYTMH;
 
 
 
 CDR2: 
 
 (SEQ ID NO: 167)
 
 DISWSGGSIYYADSVKG;
 
 
 
 CDR3: 
 
 (SEQ ID NO: 168)
 
 DHRGYGDYEGGGFDY;
or
comprising the amino acid sequence:
 
 CDR1: 
 
 (SEQ ID NO: 182)
 
 DYTMH;
 
 
 CDR2:
 
 (SEQ ID NO: 183)
 
 DISWSSGTTGYADSVKG;
 
 
 CDR3: 
 
 (SEQ ID NO: 184)
 
 DHMGYGDYEGGGFDY;
and wherein the light chain variable region comprises a CDR1, CDR2, and CDR3 region comprising the amino acid sequence:
 
 CDR1: 
 
 (SEQ ID NO: 21)
 
 QSISSY;
 
 
 
 CDR2: 
 
 (SEQ ID NO: 22)
 
 AAS;
 
 
 
 CDR3: 
 
 (SEQ ID NO: 299)
 
 QQSYSTPPT.